AUM Biosciences appoints Dr. John Patava as its Chief Operating Officer as company prepares for upcoming clinical development milestones
AUM Biosciences (AUM), an oncology-focused Asian biotechnology company that develops targeted therapeutics in oncology officially welcomes Dr. John Patava as its Chief Operating Officer.
AUM recently acquired a novel and highly selective Mnk inhibitor from A*Star. The acquisition was the first in its pipeline of targeted therapies. “This expansion of our leadership team comes at a key inflection point for AUM as we prepare for upcoming clinical stage milestones. John comes to us with core strengths in leadership, operations, personnel and program management, and his demonstrated ability to successfully lead global teams. His addition will help to ensure that AUM’s vision of ‘Asia to global’ drug development is successfully achieved”, commented Vishal Doshi, Chairman & CEO, AUM Biosciences.
Prior to joining AUM, John served as the Global Head of Scientific and Clinical Affairs at Sirtex, a global leader in cancer treatment. John was responsible for managing the company’s major regulatory submissions and intellectual property by translating the results obtained from clinical trials into commercially focused deliverables.
John was instrumental in transitioning Sirtex from a single product company to an organisation with broad capabilities in pharmaceutical development. John also oversaw clinical trials in the indications of oncology, renal medicine, Chron’s disease, multiple sclerosis, hematology and surgery. John was responsible for transitioning a pharmaceutical product, STC314, from bench to completion of Phase I program.
Before Sirtex, John was the Global Head of the Biosimilar Development Business Group at Quintiles Asia (now IQVIA), supporting various pharma companies on clinical development strategies. He also served as Head of Productivity, Delivery and Quality for clinical operations across Asia. John also held senior leadership positions at Bayer, managing clinical operations in Australia and South East Asia where he oversaw programs for the registration of regorafenib for the treatment of colorectal cancer. John holds a PhD in Physiology from the University of Sydney.
“I am very excited to be joining AUM Biosciences at this stage in the life of the company. My colleagues and I share a focus on helping address key clinical needs in Asia and there is a great opportunity to take new technologies from this region to the rest of the world”
– John Patava, COO, AUM Biosciences
John is known in the pharmaceutical industry for his extensive background in developing relationships with Medical Key Opinion Leaders and business partners.
About AUM Biosciences:
AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, we aim to create value for patients, physicians and our partners by harnessing the power of precision medicine, and digital health. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of cancers prevalent in Asia and has the potential to address global markets.
AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 70 years of high-quality oncology drug development experience combined.
Headquartered in Singapore, AUM is strategically positioned to work with, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM will have a specific focus on indications which have high unmet medical needs in Asian patients with global potential.
For more information, please visit www.aumbiosciences.com
For any queries and clarifications, please contact firstname.lastname@example.org